United States & Mass General Brigham Cancer Institute
3 shared events · Importance 3 · Last updated Aug 22, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Mass General Brigham Cancer Institute: Conducted and published the study, enhancing its reputation in cancer research.
Aug 17, 2026 · 20 articles
Tech
United States: The U.S. is the primary market for the vaccine, with over 100,000 new melanoma cases expected annually. Regulatory approval and adoption in the U.S. will be crucial for the therapy's commercial success.
Mass General Brigham Cancer Institute: The institute's experts commented on the trial, noting the potential to change treatment paradigms.
Aug 19, 2026 · 126 articles
Business
United States: Regulatory jurisdiction for potential approval of engasertib; the financing supports U.S. regulatory submissions.
Mass General Brigham Cancer Institute: Affiliation of the Principal Investigator, supporting the trial's clinical oversight.
Aug 11, 2026 · 8 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Mass General Brigham Cancer Institute interact across events, view sentiment trends, and discover connected entities.
Open Dashboard